Open AccessComparison of Brain-derived Neurotrophic Factor Level in Depressed Patients Treated with Fluoxetine and Sertraline
Author(s) -
Sonny Teddy Lisal,
Nur Aeni M. A. Fattah,
Rahmawati Nur Indah,
Saidah Syamsuddin
Publication year - 2021
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2021.6348
Subject(s) - sertraline , fluoxetine , antidepressant , medicine , serotonin reuptake inhibitor , paroxetine , brain derived neurotrophic factor , neurotrophic factors , reuptake inhibitor , depression (economics) , pharmacology , anesthesia , psychiatry , endocrinology , serotonin , hippocampus , receptor , macroeconomics , economics
Background: The Brain-Derived NeurotrophicFactor (BDNF) is the main neuronal growth factor in the brain that regulates neurogenesis, neuronal maturity, synaptic formation and plasticity. Studies showed BDNF level decreased in depression and the administration of anti depressant drugs increased BDNF level. In this study, we used fluoxetine and sertraline, which are Selective Serotonin Reuptake Inhibitor (SSRI) but had a different mechanism in influencing the BDNF levels. The purpose of this study was to compare the effect of fluoxetine and sertraline administration tothe BDNF level in depressed subjects. This study was conducted at Wahidin Sudirohusodo Hospital, Makassar, Indonesia and its affiliates from January to February 2019. Twenty outpatient subjects were diagnosed with depression based on DSM-V. The subjects were either antidepressant naïve, or dropping out of antidepressant therapy for at least 3 months since the last administration. Blood samples from each subject were taken by consecutive sampling, and BDNF levels were analyzed before and after administration of fluoxetine and sertraline for six weeks. Also, Hamilton Depression Rating Scale (HDRS) scores are measured before and after administration.
The BDNF serum was significantly increased by 100.6% (p<0,001) from the baseline level in the fluoxetine group and 75.4% in the sertraline group. HDRS score was decreased by39.5% (p<0,001) in the fluoxetine group and 30.1% in the sertraline group after six weeks of administration. This study suggests that fluoxetine was superior to sertraline in increasing the BDNF level in depression.